Babcock Genetics, Inc.

babcockgenetics.com

Babcock Genetics, Inc. is a leading supplier of swine genetics to the United States commercial industry. By utilizing cutting edge research methods, superior swine genetics, and a closed herd system, Babcock supplies its customers with a genetic base with a high probability for profitability. Babcock is an innovative company that is committed to all facets of the pork industry in addition to its own success. Minimum disease risk, excellent reproductive performance, growth rate, feed efficiency, and pork quality best describe Babcock Genetics.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech

AESTHETICS BIOMEDICAL® ANNOUNCES COLLABORATION WITH U.S. DERMATOLOGY PARTNERS OFFERING CONSUMERS LUXURY EXPERIENTIAL AESTHETIC TREATMENTS

Aesthetics Biomedical® Inc. | October 07, 2021

news image

Aesthetics Biomedical® Inc. (ABM), is pleased to announce their long-term partnership with U.S. Dermatology Partners, the largest physician-led dermatology practice in the United States. With years of experience and more than 90+ locations throughout Arizona, Colorado, Kansas, Maryland, Missouri, Oklahoma, Texas, and Virginia, U.S. Dermatology Partners combines the personal level of care found in private dermatology practices with the benefits of a network of physician experts...

Read More

Industrial Impact

PDS BIOTECH ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH THE FDA AND PREPARATION FOR THE REGISTRATIONAL TRIAL

PDS Biotechnology | October 04, 2022

news image

PDS Biotechnology Corporation a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® for the treatment of unresectable, recurrent/metastatic human papilloma virus 16-positive head and neck squamous cell carcinoma. Read More

Industrial Impact

PERSEPHONE BIOSCIENCES CLOSES $15M SEED FINANCING ROUND

Persephone Biosciences | July 20, 2022

news image

Persephone Biosciences Inc., a synthetic biology company reimagining patient and infant health through the development of microbiome-based medicines, today announced that it has closed a $15 million seed financing round. The round was co-led by First Bight Ventures and Propel Bio Partners, and included investments from Y Combinator, Fifty Years, Susa Ventures, American Cancer Society’s BrightEdge Fund, Pioneer Fund, and ZhenFund among others. “Thi...

Read More

Cell and Gene Therapy

CERES NANOSCIENCES AND GINKGO BIOWORKS PARTNER TO BRING PATHOGEN MONITORING CAPABILITIES TO LABS AROUND THE WORLD

prnewswire | September 14, 2023

news image

Ceres Nanosciences, a global leader in developing wastewater testing methods based on its Nanotrap® technology, and Ginkgo Bioworks which is building the leading platform for cell programming and biosecurity, today announced that they are partnering to bring pathogen monitoring capabilities to laboratories around the world. Pathogen monitoring and analysis capabilities, inclu...

Read More
news image

MedTech

AESTHETICS BIOMEDICAL® ANNOUNCES COLLABORATION WITH U.S. DERMATOLOGY PARTNERS OFFERING CONSUMERS LUXURY EXPERIENTIAL AESTHETIC TREATMENTS

Aesthetics Biomedical® Inc. | October 07, 2021

Aesthetics Biomedical® Inc. (ABM), is pleased to announce their long-term partnership with U.S. Dermatology Partners, the largest physician-led dermatology practice in the United States. With years of experience and more than 90+ locations throughout Arizona, Colorado, Kansas, Maryland, Missouri, Oklahoma, Texas, and Virginia, U.S. Dermatology Partners combines the personal level of care found in private dermatology practices with the benefits of a network of physician experts...

Read More
news image

Industrial Impact

PDS BIOTECH ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH THE FDA AND PREPARATION FOR THE REGISTRATIONAL TRIAL

PDS Biotechnology | October 04, 2022

PDS Biotechnology Corporation a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® for the treatment of unresectable, recurrent/metastatic human papilloma virus 16-positive head and neck squamous cell carcinoma. Read More

news image

Industrial Impact

PERSEPHONE BIOSCIENCES CLOSES $15M SEED FINANCING ROUND

Persephone Biosciences | July 20, 2022

Persephone Biosciences Inc., a synthetic biology company reimagining patient and infant health through the development of microbiome-based medicines, today announced that it has closed a $15 million seed financing round. The round was co-led by First Bight Ventures and Propel Bio Partners, and included investments from Y Combinator, Fifty Years, Susa Ventures, American Cancer Society’s BrightEdge Fund, Pioneer Fund, and ZhenFund among others. “Thi...

Read More
news image

Cell and Gene Therapy

CERES NANOSCIENCES AND GINKGO BIOWORKS PARTNER TO BRING PATHOGEN MONITORING CAPABILITIES TO LABS AROUND THE WORLD

prnewswire | September 14, 2023

Ceres Nanosciences, a global leader in developing wastewater testing methods based on its Nanotrap® technology, and Ginkgo Bioworks which is building the leading platform for cell programming and biosecurity, today announced that they are partnering to bring pathogen monitoring capabilities to laboratories around the world. Pathogen monitoring and analysis capabilities, inclu...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us